ArticleCureus2026
Assessing the Impact of Dermatophytosis on Quality of Life Using the Dermatology Life Quality Index: A Real-World Cross-Sectional Study From India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveDermatophytosis has emerged as a chronic, recurrent, and high-burden dermatosis in India, with increasing reports of extensive involvement and treatment difficulty. Although clinical assessment is routinely performed, patient-reported quality of life (QoL) evaluation is inconsistently integrated into practice. This multicentric real-world study aimed to assess the QoL burden associated with dermatophytosis using the Dermatology Life Quality Index (DLQI).
methodsA cross-sectional study was conducted between April and October 2025 involving clinically diagnosed dermatophytosis patients attending the outpatient department from 325 centres across India with Independent Ethics Committee approval. The primary endpoint of the study was to assess DLQI in these patients, whereas secondary endpoints included evaluation of the association between DLQI scores and demographic, clinical, occupational, comorbidity-related, and treatment-related variables.
resultsWe analysed the data of 2776 patients who met the inclusion criteria, highlighting the predominance of males (57%). The median DLQI was 12 (interquartile range (IQR) 8-17), indicating a very large impact of dermatophytosis on daily life. The QoL impairment increased progressively with disease extent, demonstrating a clear severity impact correlation relationship between lesion burden and DLQI (p<0.001). The DLQI differed significantly across age groups (p<0.001) and was markedly higher in patients with facial (p<0.001) and trunk/back involvement (p<0.001). Occupations associated with high sweat and friction exposure showed the greatest impairment (p=0.003). Systemic comorbidities, including obesity, diabetes, hepatic, cardiac, and renal disorders, were consistently associated with worse DLQI (all p<0.001). Treatment regimens significantly influenced patient-reported outcomes (p<0.001), with super-bioavailable(SBA) itraconazole combined with topical therapy demonstrating the most favorable QoL profile.
conclusionThe QoL impairment in these patients is most pronounced with facial involvement, higher lesion counts, high sweat/friction occupations, and systemic comorbidities. Notably, treatment with SBA itraconazole in combination with topical antifungal therapy was associated with lower DLQI. These findings emphasize the importance of individualized management, prioritizing patients with visible/extensive disease and medical comorbidities for more intensive treatment and supportive counseling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.